RxDoctor Payments Data

Mary Dotson

Family · Athens, GANPI 1508977240

Payments from drug & device makers

$4,942in general payments, 2019–2025

Across 222 payments — averaging $22.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$565
  • Regeneron Healthcare Solutions, Inc.$379
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$311
  • Takeda Pharmaceuticals U.S.A., Inc.$301
  • Sanofi$267
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,58493%
  • Education$3587%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,942 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$34,071
Medicare patients
296
Services billed
419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab11$149,252
LinzessLinaclotide112$79,590
Dexlansoprazole DrDexlansoprazole20$5,464
Lubiprostone32$4,047
Sucralfate61$3,785
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl213$3,663
MovantikNaloxegol Oxalate12$3,049
Famotidine169$2,844
Ondansetron OdtOndansetron47$1,481
Pantoprazole Sodium85$948
Omeprazole61$816
Lactulose30$489
Ondansetron Hcl17$398
Esomeprazole Magnesium21$358
Hydrocortisone18$290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,321$79,590112 claims
Redhill Biopharma Inc.Movantik$86$3,04912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →